



50

Golden Jubilee Annual conference of  
Mumbai Hematology Group (MHG)

soho  India

Essence of ASH

With international guest faculty

Friday-Sunday

15th to 17th of January 2027

**Venue:**

Jio World Convention Centre  
Bandra Kurla Complex  
Bandra (East) Mumbai, India.

soho   
society of hematologic oncology

Click on the link underneath for registering:

## The Society of Hematologic Oncology (SOHO)

The Society of Hematologic Oncology (SOHO) is a premier international, non-profit professional organization dedicated exclusively to advancing research, education, prevention, clinical trials, and patient care in the field of hematologic malignancies and related disorders.

Founded in 2012 with its headquarters in Houston, Texas, SOHO was established to address a critical gap in medical societies: while general oncology groups often focus heavily on solid tumors, and standard hematology groups dedicate significant portions to benign blood disorders, SOHO was created to focus exclusively on malignant hematology (such as leukemias, lymphomas, myeloma, and MDS/MPN).

Its global network supports over 12,000 members spanning more than 128 countries, serving a diverse community of clinicians, research scientists, pathologists, nurses, and allied healthcare professionals.





**Executive committee**  
Mumbai Hematology Group

**President**

Dr. M. B. Agarwal

**Vice-President**

Dr. S D Banavali

**Secretary**

Dr. Rucha Patil

**Treasurer**

Dr. Subhaprakash Sanyal

**Members**

Dr. VA Arun

Dr. Asha Shah

Dr. Bipin Kulkarni

Dr. Navin Khattry

Dr. Roshan Colah

Dr. Shanaz Khodaiji

Dr. Shrimati Shetty

Dr. Shubhangi Agale

Dr. Vidisha Mahajan

Dr. Vrinda Kulkarni



## Faculty - International

Dr. Delphine Rea, France

Dr. Hanny Al-Samkari, USA

Dr. María Victoria Mateos, Spain

Dr. Naval Daver, USA

Dr. Nitin Jain, USA

Dr. Ranjan Advani, USA



## Faculty - National

- |                                       |                                  |
|---------------------------------------|----------------------------------|
| Dr. Aditya Jandial, Chandigarh        | Dr. Prantar Chakrabarti, Kolkata |
| Dr. Amit Khurana, Surat               | Dr. Priyanka Samal, Bhubaneswar  |
| Dr. Ankur Ahuja, Pune                 | Dr. R. K. Jena, Cuttack          |
| Dr. Arijit Nag, Kolkata               | Dr. Rajan Kapoor, Leh            |
| Dr. Ashish Dixit, Bengaluru           | Dr. Rajat Bhattacharyya, Kolkata |
| Dr. Avinash Kumar Singh, Patna        | Dr. Revathi Raj, Chennai         |
| Dr. Chandrakala S, Bengaluru          | Dr. Riya Ballikar, Nagpur        |
| Dr. Chirasree Sanyal, Kolkata         | Dr. Sachin Jadhav, Bengaluru     |
| Dr. Debdatta Basu, Puducherry         | Dr. Sameer Melinkeri, Pune       |
| Dr. Dinesh Bhurani, Delhi             | Dr. Sanjeevan Sharma, Delhi      |
| Dr. Faheema Hasan, Prayagraj          | Dr. Satish Kumar A, Bengaluru    |
| Dr. Ganesh Jaishetwar, Hyderabad      | Dr. Seema Bhatwadekar, Vadodara  |
| Dr. Hemant Malhotra, Jaipur           | Dr. Sharat Damodar, Bengaluru    |
| Dr. Jina Bhattacharyya, Guwahati      | Dr. Shilpa Bhartia, Kolkata      |
| Dr. John Abraham, CMC, Ludhiana       | Dr. Siddhesh Kalantri, Nashik    |
| Dr. Kiruthiga K. G., Pune             | Dr. Sonia Nityanand, Lucknow     |
| Dr. Lalit Kumar, Delhi                | Dr. Sudha Sinha, Hyderabad       |
| Dr. M. Joseph John, Ludhiana          | Dr. Sunil Bhat, Bengaluru        |
| Dr. Maitreyee Bhattacharyya           | Dr. Sunit Lokwani, Indore        |
| Dr. Mallikarjun Kalashetty, Bengaluru | Dr. Sweta Lunkad, Pune           |
| Dr. Manoj Kumar, Ahmedabad            | Dr. Tara Roshni Paul, Hyderabad  |
| Dr. Nataraj K. S., Bengaluru          | Dr. Tuphan Kanti Dolai           |
| Dr. Neeraj Sidharthan, Kochi          | Dr. Vandana Bharadwaj, Bengaluru |
| Dr. Nidhi Jain, Ahmedabad             | Dr. Velu Nair, Gandhinagar       |
| Dr. Nikhil Kumar M, Kochi             | Dr. Vikram Mathews, Vellore      |
| Dr. Nilesh Wasekar, Nashik            | Dr. Vinay Bohara, Indore         |
| Dr. Pankaj Malhotra, Chandigarh       |                                  |



## Faculty - Local

Dr. Aditi Shah Kaskar	Dr. Kunal Sehgal	Dr. Purna Kurkure
Dr. Alok Shetty	Dr. Lingaraj Nayak	Dr. Purva Kanvinde
Dr. Amar Dasgupta	Dr. M. B. Agarwal	Dr. Rajesh Patil
Dr. Ambreen Pandrowala	Dr. Malay Mukherjee	Dr. Reetu Jain
Dr. Anjana Sainani	Dr. Mamta Manglani	Dr. Ritika Khurana
Dr. Ankita Pandey	Dr. Manisha Madkaikar	Dr. Rucha Patil
Dr. Archana Swami	Dr. Manju Sengar	Dr. Sameer Tulpule
Dr. Arundhati Athalye	Dr. Mukesh Desai	Dr. Sangeeta Mudaliar
Dr. Asha Shah	Dr. Muralidaran C	Dr. Santanu Sen
Dr. Ashish Bakshi	Dr. N. D. Moulick	Dr. Shanaz Khodaiji
Dr. Ayushi Agrawal	Dr. Namita Padwal	Dr. Shilpa Gupta
Dr. Balkrishna Padate	Dr. Naveed Tamboli	Dr. Shrinath Kshirsagar
Dr. Bani B. Ganguly	Dr. Navin Khattry	Dr. Shrutika Java
Dr. Bhavna Parikh	Dr. Nikhil Patkar	Dr. Shweta Bansal
Dr. Bipin Kulkarni	Dr. Nishant Jindal	Dr. Subhaprakash Sanyal
Dr. Darshana Rane	Dr. Omkar Khandkar	Dr. Sujata Sharma
Dr. Dipsha Kriplani	Dr. P. G. Subramanian	Dr. Sumeet Gujral
Dr. Farah Jijina	Dr. Parth Ganatra	Dr. Swati Kanakia
Dr. Gaurav Chatterjee	Dr. Prashant Tembhare	Dr. Tapan Saikia
Dr. Girish Rajadhyaksha	Dr. Prathamesh Kulkarni	Dr. VA Arun
Dr. Hamza Dalal	Dr. Priti Mehta	Dr. Vidhisha Mahajan
Dr. Jai Juvekar	Dr. Prochi Madon	Dr. Vrinda Kulkarni
Dr. Jyoti Chirmade	Dr. Punit Jain	



## Mumbai Hematology Group

Dear Colleagues & Students,

It is our distinct privilege to invite you to the 50th Golden Jubilee Annual conference of Mumbai Hematology Group (MHG), SOHO India & Essence of ASH.

In an era of digital fatigue, we are proud to announce this as a strictly in-person (physical) summit. This is a deliberate choice to foster the high-level scientific discourse, spontaneous networking, and personal camaraderie that only a face-to-face gathering can provide.

We have curated a faculty of eminent international experts to bridge the gap between global innovations and practical clinical application in both classical and malignant hematology.

Joining them is a "Galaxy" of premier Indian faculty, bringing local context to the latest breakthroughs.

I am delighted to inform you that SOHO (The Society of Hematologic Oncology) India has joined hands with us for this academic event.

We also bring the most critical updates from American Society of Hematology (ASH) directly to you, distilled for maximum impact on your practice.

This is your premier opportunity to reconnect with mentors, engage with peers, and build the professional relationships that define our field.

We anticipate a record turnout this year. We urge you to register early and ensure your place at what promises to be the most vibrant and transformative educational event of 2027.

Let us gather in Mumbai to celebrate science, friendship, and the future of hematology.

Yours sincerely,



**Dr. Rucho K. Patil**  
Secretary, MHG




**Dr. M.B. Agarwal**  
President, MHG



## Faculty - International



Dr. Delphine Rea, France



Dr. Hanny Al-Samkari, USA




Dr. María Victoria Mateos, Spain



Dr. Naval Daver, USA



Dr. Nitin Jain, USA



Dr. Ranjana Advani, USA



## Faculty - International




### Dr. Delphine Rea, MD, PhD

Professor  
President of the French CML Study Group (Fi-LMC)  
Hematologist, Attending Physician  
Head of the Chronic Myeloid Leukemia Tumor Board  
Hematology Department  
Saint-Louis Hospital  
Paris, France

- Dr. Delphine Rea is appointed at Saint-Louis University Hospital, Paris, France where she works as a physician in the Department of Hematology.
- Her main clinical and research interest focuses on malignant myeloid disorders.
- She is responsible for the Chronic Myeloid Leukemia clinical care and research program.
- She has been the principal investigator or investigator of many academic- or industry-sponsored clinical trials dedicated to CML, including pivotal studies that have led to the approval of tyrosine kinase inhibitors or treatment-free remission studies.
- She belongs to the board of directors of the French cooperative group of CML (Fi-LMC), contributes to the CML project of the European LeukemiaNet, to the organization committee of European School of Haematology (ESH) iCMLf annual conference, to the Society of Hematologic Oncology (SOHO) annual meeting education committee and to the scientific advisory board of iCMLf.



## Faculty - International



### Dr. Hanny Al-Samkari, MD

Classical Hematologist and Clinical Investigator  
The Peggy S. Blitz Endowed Chair in Hematology/Oncology  
Co-Director, Hereditary Hemorrhagic Telangiectasia Center  
Massachusetts General Hospital  
Associate Professor of Medicine  
Harvard Medical School  
Boston  
Massachusetts, USA

- Dr. Hanny Al-Samkari is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School.
- He is a classical hematologist and NIH-funded clinical investigator and clinical trialist.
- He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence.
- His clinical and research interests are in hemostasis, thrombosis, and hemolysis, with focuses in HHT, immune thrombocytopenia, and hemolytic anemias.
- As a clinical investigator, Dr. Al-Samkari is an internationally recognized expert in the clinical development of novel therapeutics for these disorders and serves as the lead principal investigator for multiple ongoing clinical trials.
- He is the current Executive Editor of Hematology: *The ASH Education Program*, an American Society of Hematology peer-reviewed publication, and has published over 150 peer-reviewed manuscripts.
- His original research has been featured in *The New England Journal of Medicine*, *The Lancet*, *Annals of Internal Medicine*, and *Blood*, among other top peer-reviewed journals in hematology and medicine.



## Faculty - International



**Dr María-Victoria Mateos, MD, PhD**

Consultant Physician  
Hematology Department  
Associate Professor of Medicine  
University of Salamanca  
Spain

- Consultant Physician in the Haematology Department.
- Associate Professor of Medicine at the University of Salamanca, Spain
- She is the Director of the Myeloma Program & co-ordinates Clinical Trials Unit in Salamanca's University Hospital Haematology Department.
- She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials.
- She has coordinated many clinical trials in elderly and smoldering MM patients that have profoundly influenced current options for treating these patient populations.
- She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH.
- She has published over 250 papers in peer-reviewed international journals, some of which have become key references in Myeloma field.
- She is Associate Editor of myeloma in Annals of Haematology since 2011 and has acted as a reviewer for top journals such as NEJM, Lancet and Lancet Oncology.
- Among her invited presentations, she has recently contributed to the educational sessions of EHA from 2012, ASH from 2013 & ASCO 2015 and EHA 2016.
- She has served on the EHA's Scientific Program Committee and Advisory Board since 2013 until 2023, and on the ASH Scientific Committee on plasma cell diseases in 2015-23.
- She is a Councilor on the EHA Board from 2015 for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee.
- She has published over 200 original papers in international journals. Her areas of interest include multiple myeloma, the biology of plasma cells and the new drugs development.



## Faculty - International



### Dr. Naval Daver

Co-section, Head AML  
Director, Leukemia Research Alliance Program  
Professor of Medicine  
Department of Leukemia  
MD Anderson Cancer Center  
Houston, Texas, USA

- Dr. Naval Daver is Co-section, Head AML
- He is Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX.
- He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease and is principal investigator on more than 25 ongoing clinical trials in these diseases, including multiple potential national and international registration studies and label enabling trials.
- These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel and rational combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance.
- He is especially interested in developing FLT3 inhibitor based combinations, monoclonal antibodies, immune checkpoints, CD47, NK and T-cellular therapy approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials.
- He has published over 450 peer-reviewed PubMed indexed manuscripts and is on the editorial board of hematology journals.
- He also serves as Chair on numerous international leukemia meetings and educational platforms.



## Faculty - International



### Dr. Nitin Jain

Professor  
Department of Leukaemia  
MD Anderson Cancer Center  
Houston, Texas, USA

- Dr. Nitin Jain, M.D., is a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
- He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002.
- He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee, Wisconsin.
- He then completed a year of clinical fellowship in Leukemia at MD Anderson Cancer Center followed by another year of Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center in New York.
- He then pursued fellowship in Hematology/Oncology at the University of Chicago. He joined as a faculty member in the Department of Leukemia at MD Anderson Cancer Center in 2012.
- He treats patients with acute and chronic leukemia with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
- His research interests focus on new drug development for patients with leukemia, especially CLL and ALL.
- He is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, combination of ibrutinib and chemotherapy (iFCG regimen) in CLL, checkpoint inhibitors in Richter transformation, trial with JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, and off-the-self allogeneic CART in B-ALL.
- The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019.
- He has published papers in prominent journals including NEJM, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, Leukemia Research and others.
- He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO).
- He secured first rank at the national level in India in the medical school (AIIMS) entrance examination.
- He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016.
- He has served as a faculty on American Society of Hematology CRTI workshop for year 2017 and 2018.
- He served as a speaker at the education session on CLL at ASH 2018 and at ASH Highlights of North America, Mediterranean, and Latin America.
- He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award.



## Faculty - International



**Dr. Ranjana Advani, M.D.**  
Saul A Rosenberg Professor of Lymphoma  
Stanford Cancer Institute  
Stanford, California, USA

- Ranjana H. Advani, MD is the Saul Rosenberg Professor of Lymphoma and serves as the Physician Leader of the Lymphoma Clinical Care Program at Stanford Cancer Institute, Stanford, California, USA
- She specializes in research and treatment of Hodgkin and non-Hodgkin lymphomas and has developed a broad collaborative investigative program, encompassing clinical trials and translational correlates.
- She is the Principal Investigator on numerous clinical trials.
- She currently serves on the National Comprehensive Cancer Network (NCCN) non-Hodgkin and Hodgkin Lymphoma (chair) guidelines panel, Lymphoma Core Committee of the Eastern Cooperative Oncology Group (ECOG) and the National Cancer Institute Lymphoma Steering Committee.
- Board Certification: American Board of Internal Medicine, Medical Oncology (2009)
- Fellowship: Stanford University Hematology and Oncology Fellowship (1996).
- Residency: Stanford University Internal Medicine Residency (1990).
- Internship: Santa Clara Valley Medical Center Internal Medicine Residency (1987)
- Medical Education: Bombay University (1982)




## Lectures by international faculty



### Dr. Delphine Rea, France

- New drugs to in CML
- Genomic abnormalities in CML: Should AGA drive 1st line treatment choices?
- Combination therapies in CML
- TFR: next steps
- Case discussion session



### Dr. Hanny Al-Samkari, USA

- Emerging Novel Therapies in Immune Thrombocytopenia
- Modern Optimized Treatment of Chemotherapy-induced Thrombocytopenia
- Emerging Novel Therapies in Hereditary Hemorrhagic Telangiectasia
- Pyruvate Kinase Activation in Thalassemia and Rare Red Cell Disorders
- Thromboembolism in ITP
- Optimized Use of TPO-RAs
- Case discussion session



### Dr. María Victoria Mateos, Spain

- Smoldering Myeloma: What is the appropriate management in 2027?
- Management of Newly Diagnosed Myeloma patients in 2027
- Management of MM patients in early relapses
- How to manage today patients in late advanced stages of the disease
- Case discussion session




### Dr. Naval Daver, USA

- Optimizing frontline Intensive chemotherapy approaches in 2027
- Targeted therapies in AML: optimal timing, use and response monitoring
- Management of frontline MDS: Key updates for 2027
- Case discussion session



### Dr. Nitin Jain, USA

- How do I treat Firstline CLL in 2027 ?
- New emerging drugs in CLL: role of BTK degraders and CAR-T
- CD19 CAR-T as consolidation treatment in adult B-ALL: an emerging paradigm
- CAR-T in T-ALL: an unmet medical need.
- Case discussion session



### Dr. Ranjana Advani, USA

- Non-Hodgkin Lymphoma: highlights from ASH 2026
- Hodgkin Lymphoma: highlights from ASH 2026
- Controversies in management of Early Stage Hodgkin Lymphoma
- How do I treat newly diagnosed DLBCL ?
- Case discussion session



# Sample abstract

Please select one : This paper is for Oral / Poster best paper award session

## First Report of Molecular Characterization of Congenital Dyserythropoietic Anaemia Type I with a CDAN1 gene mutation diagnosed by Next Generation Sequencing panel

Presenting author: Arati Nandan Saptarshi

Co-authors: Rashmi Dongerdiye, Tejashree Anil More, Dr. Prabhakar S. Kedar

ICMR-National Institute of Immunohaematology, 13th floor, New Multistoried Building, KEM Hospital, Parel, Mumbai 400012

### Abstract:

Background: Congenital dyserythropoietic anaemias (CDAs) are a rare, heterogeneous group of disorders characterized by ineffective erythropoiesis. CDA I is very rare and caused due to mutations in the CDAN1 or c15orf41 gene. There is no report on the molecular characterization of CDA I in the Indian population. An 8-year-old transfusion-dependent patient was referred for haemolytic anaemia workup. Common causes of congenital haemolytic anaemia were ruled out. A bone marrow aspiration study showed erythroid hyperplasia with mild dyserythropoiesis. Thus, the patient was considered for molecular characterization using next-generation sequencing.

### Objective:

Diagnosis of unexplained congenital anaemia using next-generation sequencing.

### Method:

Next-generation sequencing panel was used for identification of the disease-causing variant; bioinformatics tools were used to predict pathogenicity of the variant and functional validation was performed by gene expression studies using quantitative real-time PCR.

### Results:

Red cell membrane, enzyme, hemoglobinopathy, and autoimmune hemolytic anaemia studies were normal. Bone marrow aspiration study showed erythroid hyperplasia with mild dyserythropoiesis. The patient showed c. 2671C>T, p. Arg891Cys variant in the CDAN1 gene using next-generation sequencing. Bioinformatics tools like SIFT, PolyPhen 2.0 predicted the variant to be damaging and deleterious. The expressions of CDAN1 and c15orf41 genes studied using quantitative real-time PCR were significantly reduced as compared to healthy controls.

### Conclusion:

Next-generation sequencing confirmed the diagnosis of CDA I in a patient who underwent excessive investigation earlier. CDA, being clinically similar to other prevalent causes of anaemia, should be kept in mind especially when the common causes have already been ruled out. Further, the use of in-silico tools and gene expression analysis validated the functional impact of this variant.

### Correspondence:

Arati Nandan Saptarshi, PhD Student, ICMR - National Institute of Immunohaematology, 13th floor, NMS Building, KEM Hospital Campus, Parel, Mumbai - 400012

Email ID: arati611@gmail.com

Cell: 8550903330



## Registration details

Category	Up to 30th September 2026	Up to 31st October 2026	Up to 30th November 2026	From 1st December 2026 onwards including Spot Registration
MHG members *	₹ 2000	₹ 4000	₹ 6000	₹ 8000
Students **	₹ 1000	₹ 2000	₹ 3000	₹ 4000
Delegates	₹ 3000	₹ 6000	₹ 9000	₹ 12000
Trade Registration	₹ 5000	₹ 10000	₹ 15000	₹ 20000
International Delegate	\$ 200	\$ 300	\$ 400	\$ 500

**Note:** \* Membership number must be forwarded.

\*\* Proof to be submitted

### Registration fee is non-refundable

Click on the link underneath for registering:  
[https](https://www.mhgindia.com)



Under the aegis of

### Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,

804-A, Dr. B. Ambedkar Road, Dadar TT, Mumbai 400014.

Email ID: mbagarwal1@gmail.com Website: www.mhgindia.com